Comparative Pharmacology
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus NAPROXEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus NAPROXEN.
MEPROBAMATE AND ASPIRIN vs NAPROXEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate is a carbamate derivative that acts as a CNS depressant, potentiating GABA-A receptor activity and inhibiting polysynaptic spinal reflexes. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Aspirin 325 mg and meprobamate 200 mg orally every 6 to 8 hours as needed for pain or anxiety. Maximum daily dose: aspirin 3.9 g, meprobamate 1.6 g.
250-500 mg orally twice daily; maximum 1.5 g/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateNaproxen + Gatifloxacin
"Naproxen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateNaproxen + Rosoxacin
"Naproxen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateNaproxen + Levofloxacin
"Naproxen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateNaproxen + Trovafloxacin
"Naproxen may increase the neuroexcitatory activities of Trovafloxacin."
Aspirin: 15-20 minutes (parent drug), but salicylate half-life is dose-dependent: 2-3 hours for low doses, 15-30 hours for high doses. Meprobamate: 6-17 hours (mean 10 hours), prolonged in overdose or hepatic impairment.
Terminal elimination half-life 12-17 hours (mean 14 hours); permits twice-daily dosing. Half-life prolonged in elderly and hepatic impairment.
Aspirin: Renal excretion of salicylates (75% as salicyluric acid, 10% as salicylic acid, 10% as phenolic glucuronide, 5% as acyl glucuronide). Meprobamate: Renal excretion (10-20% unchanged, 80-90% as hydroxylated metabolites) and biliary excretion (<5%).
Primarily renal (95% as unchanged naproxen and 6-O-desmethylnaproxen); <5% fecal via biliary excretion.
Category D/X
Category D/X
NSAID / Antiplatelet
NSAID